T-cell-targeted immunotherapy.
The pace of T-cell research is matched only by the speed with which fundamental advances are being developed as new therapies. This report from a recent meeting updates developments in a number of immunointervention strategies.
Feldmann
M
M
Charing Cross Sunley Research Centre, Hammersmith, London, UK.
June
C H
CH
McMichael
A
A
Maini
R
R
Simpson
E
E
Woody
J N
JN
D016915:AIDS Vaccines / Q000008:administration & dosage; D000818:Animals; D016207:Cytokines / Q000627:therapeutic use; D015686:Gene Products, env / Q000276:immunology; D006678:HIV / Q000276:immunology; D019302:HIV Envelope Protein gp160; D015658:HIV Infections / Q000517:prevention & control; D006801:Humans; D007167:Immunotherapy; D010455:Peptides / Q000627:therapeutic use; D011498:Protein Precursors / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D014611:Vaccination
D016915:AIDS Vaccines; D016207:Cytokines; D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; D010455:Peptides; D011498:Protein Precursors; D011994:Recombinant Proteins